Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-31true2023-04-01falseNo description of principal activity66The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 07932529 2023-04-01 2024-03-31 07932529 2022-04-01 2023-03-31 07932529 2024-03-31 07932529 2023-03-31 07932529 c:Director1 2023-04-01 2024-03-31 07932529 c:Director2 2023-04-01 2024-03-31 07932529 c:Director3 2023-04-01 2024-03-31 07932529 c:RegisteredOffice 2023-04-01 2024-03-31 07932529 d:CurrentFinancialInstruments 2024-03-31 07932529 d:CurrentFinancialInstruments 2023-03-31 07932529 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 07932529 c:FullAccounts 2023-04-01 2024-03-31 07932529 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 07932529 c:Micro-entities 2023-04-01 2024-03-31 07932529 e:PoundSterling 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure
Registered number: 07932529










OSTEOPOROSIS RESEARCH LTD
FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

 
OSTEOPOROSIS RESEARCH LTD
 

COMPANY INFORMATION


Directors
J. Kanis 
R. Kanis-Buck 
E. V. McCloskey 




Registered number
07932529



Registered office
1st Floor Sackville House
143-149 Fenchurch Street

London

EC3M 6BL





 
OSTEOPOROSIS RESEARCH LTD
 

CONTENTS



Page
Balance Sheet
 
1
Notes to the Financial Statements
 
2


 
OSTEOPOROSIS RESEARCH LTD
REGISTERED NUMBER: 07932529

BALANCE SHEET
AS AT 31 MARCH 2024

2024
2023
£
£

Called up share capital not paid
99
99

Current assets
420,960
340,627

Creditors: amounts falling due within one year
(21,389)
(8,506)

Net current assets
 
 
399,571
 
 
332,121

Net assets
399,670
332,220



Capital and reserves
399,670
332,220



The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities regime in Part 15 of the Companies Act 2006 and FRS 105: The Financial Reporting Standard applicable to the micro-entities regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The Company has opted not to file the Profit and Loss Account in accordance with the provisions applicable to companies subject to the small companies regime, under section 444 of the Companies Act 2006.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 
16 October 2024.




J. Kanis
Director

The notes on page 2 form part of these financial statements.

Page 1

 
OSTEOPOROSIS RESEARCH LTD
REGISTERED NUMBER: 07932529

1.


General information

Osteoporosis Research Ltd (company number: 07932529) having its registered office at 1st Floor Sackville House, 143-149 Fenchurch Street, London, EC3M 6BL, is a private limited company incorporated in England and Wales.


2.


Employees

The average monthly number of employees, including the directors, during the year was 6 (2022: 6).


3.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £970 (2023: £601). Contributions totalling £76 (2023: £492) were payable to the fund at the Balance Sheet date and are included in creditors.


4.


Related party transactions

As at the year end, £53,570 (2023: £74,910) was owed from a director of the Company. No interest is chargeable on the balance, which was settled within 9 months of the year end.

Page 2